Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status

Andrology

Volumn 1, Issue 6, 2013, Pages 906-912

  Ng Tang Fui, M ^a,b   Hoermann, R ^a   Cheung, A S ^a,b   Gianatti, E J ^a,b   Zajac, J D ^a,b   Grossmann, M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

Ageing; Diabetes; Obesity; Testosterone

Indexed keywords

SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

AGEING; DIABETES; OBESITY; TESTOSTERONE;

ADULT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MIDDLE AGED; OBESITY; PREVALENCE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; VICTORIA;

EID: 84886409827     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/j.2047-2927.2013.00124.x     Document Type: Article

References (33)

1. Allan CA & McLachlan RI. (2010) Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 17, 224-232.
2. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT & Wittert GA. (2011) Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 96, 3007-3019.
3. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R et al. (2006) Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2, 146-159.
4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95, 2536-2559.
5. Biswas M, Hampton D, Newcombe RG & Rees DA. (2012) Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf) 76, 665-673.
6. Camacho EM, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM et al. (2013) Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 168, 445-455.
7. Chandel A, Dhindsa S, Topiwala S, Chaudhuri A & Dandona P. (2008) Testosterone concentration in young patients with diabetes. Diabetes Care 31, 2013-2017.
8. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A et al. (2010) Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 34, 528-540.
9. van Dam EW, Dekker JM, Lentjes EG, Romijn FP, Smulders YM, Post WJ et al. (2003) Steroids in adult men with type 1 diabetes: a tendency to hypogonadism. Diabetes Care 26, 1812-1818.
10. Danielson KK, Drum ML & Lipton RB. (2008) Sex hormone-binding globulin and testosterone in individuals with childhood diabetes. Diabetes Care 31, 1207-1213.
11. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A & Dandona P. (2004) Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89, 5462-5468.
12. Ding EL, Song Y, Malik VS & Liu S. (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 295, 1288-1299.
13. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N et al. (2009) Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361, 1152-1163.
14. Grossmann M. (2011c) Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 96, 2341-2353.
15. Grossmann M & Zajac JD. (2011b) Management of side effects of androgen deprivation therapy. Endocrinol Metab Clin North Am 40, 655-671.
16. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S et al. (2008) Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93, 1834-1840.
17. Grossmann M, Gianatti EJ & Zajac JD. (2010) Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 17, 247-256.
18. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL & Zajac JD. (2011a) Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 194, 301-306.
19. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D et al. (2011) Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 74, 377-383.
20. Handelsman DJ & Zajac JD. (2004) Androgen deficiency and replacement therapy in men. Med J Aust 180, 529-535.
21. Heufelder AE, Saad F, Bunck MC & Gooren L. (2009) Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30, 726-733.
22. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR & Liu PY. (2012) Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 167, 531-541.
23. Kapoor D, Aldred H, Clark S, Channer KS & Jones TH. (2007) Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30, 911-917.
24. Maric C, Forsblom C, Thorn L, Waden J & Groop PH. (2010) Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids 75, 772-778.
25. Saad F, Aversa A, Isidori AM & Gooren LJ. (2012) Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 8, 131-143.
26. Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A et al. (2012) Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf) 77, 755-763.
27. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA & Handelsman DJ. (2005) Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 90, 5928-5936.
28. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM et al. (2012) Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 97, 1508-1516.
29. Travison TG, Araujo AB, Kupelian V, O'Donnell AB & McKinlay JB. (2007) The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 92, 549-555.
30. Vermeulen A, Verdonck L & Kaufman JM. (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84, 3666-3672.
31. Wallace IR, McKinley MC, Bell PM & Hunter SJ. (2013) Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 78, 321-329.
32. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW et al. (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93, 2737-2745.
33. Yeap BB. (2009) Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 5, 113-121.